1. Home
  2. FT vs GALT Comparison

FT vs GALT Comparison

Compare FT & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$8.26

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$2.73

Market Cap

177.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FT
GALT
Founded
1988
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
177.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FT
GALT
Price
$8.26
$2.73
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.50
AVG Volume (30 Days)
63.0K
300.4K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.97
$1.12
52 Week High
$7.23
$7.13

Technical Indicators

Market Signals
Indicator
FT
GALT
Relative Strength Index (RSI) 71.67 36.96
Support Level $8.08 $2.62
Resistance Level $8.10 $2.88
Average True Range (ATR) 0.07 0.21
MACD 0.01 0.04
Stochastic Oscillator 73.98 21.74

Price Performance

Historical Comparison
FT
GALT

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: